COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

CPTAC Accelerates Precision Proteomics Biomedical Research

The accurate quantitation of proteins or peptides using Mass Spectrometry (MS) is gaining prominence in the biomedical research community as an alternative method for analyte measurement. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) investigators have been at the forefront in the promotion of reproducible MS techniques, through the development and application of standardized proteomic methods for protein quantitation on biologically relevant samples.

New England Peptide, Inc., in coordination with investigators from CPTAC and others, today announced the launch of Tryptides™, a new product line of stable isotope labeled peptide standards for biomarker discovery. The catalog offers thousands of fragments spanning over 1000 proteins of interest and is accessible to the biomedical research community who can search by protein name, UniProt ID number, gene or peptide sequence.

Many of the peptides have been characterized by CPTAC Investigators as part of its Assay Development Working Group. CPTAC standardized assays - along with MS data - can be found at the National Cancer Institute’s Proteomics Assay Portal (, whose goal is to disseminate highly characterized, targeted proteomic assays to the community to standardize protein or peptide measurements and harmonize results across the community.

The catalog of Tryptides™ is designed and optimized for Multiple Reaction Monitoring Mass Spectrometry (MRM-MS), with very high purity and accurate quantitation, and is now accessible to the biomedical research community through New England Peptide.

Brand names cited here are used for identification purposes and do not constitute an endorsement by CPTAC or NCI.